

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangsu Recbio Technology Co., Ltd.

江蘇瑞科生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02179)

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

References are made to the announcements of Jiangsu Recbio Technology Co., Ltd. (the “**Company**”) dated May 21, 2025, January 30, 2026, February 6, 2026 and April 30, 2026 (the “**Announcements**”) in relation to, among others, the Company’s proposed participation in the H Share Full Circulation, the issuance of the filing notice by the CSRC in respect of the Company’s H Share Full Circulation plan, the grant of listing approval by the Stock Exchange for the H Share Full Circulation plan of the Company and the completion of H Share Full Circulation by the Company. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

As stated in the Announcements, the Company has completed the conversion of an aggregate of 141,953,489 unlisted shares into H Shares on April 29, 2026. On this basis, the Company made corresponding adjustments to the relevant contents of the Articles of Association and has recently completed the industrial and commercial filing for the amended Articles of Association.

Details of the amendments to the Articles of Association are set out as follows:

Article No.	Before amendment	After amendment
Article 21	The Company has a total of 626,075,702 shares, including 297,937,013 domestic shares, accounting for 47.59% of the total share capital of the Company; and 328,138,689 foreign shares, accounting for 52.41% of the total share capital of the Company; and 316,138,689 H shares, accounting for 50.50% of the total share capital of the Company; and the foregoing shares are all ordinary shares.	The Company has a total of 626,075,702 shares, including 297,937,013 167,983,524 domestic shares, accounting for 47.59 26.83 % of the total share capital of the Company; and 328,138,689 foreign shares, accounting for 52.41% of the total share capital of the Company; and 316,138,689 458,092,178 H shares, accounting for 50.50 73.17 % of the total share capital of the Company; and the foregoing shares are all ordinary shares.

Save for the above amendments, other provisions of the Articles of Association remain unchanged.

For the full text of the amended Articles of Association, please refer to the HKEXnews website of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and the website of the Company (www.recbio.cn).

By order of the Board
Jiangsu Recbio Technology Co., Ltd.
Mr. XU Haoyu
Chairman

Jiangsu Province, the PRC, August 17, 2026

As at the date of this announcement, the Board comprises Mr. XU Haoyu as the chairman of the Board and a non-executive Director, Dr. LIU Yong, Ms. WANG Jing and Mr. WEI Qifang as executive Directors, Dr. WANG Ruwei, Dr. ZHANG Jiabin, Dr. ZHOU Hongbin and Mr. HU Houwei as non-executive Directors, and Dr. XIA Lijun, Mr. LIANG Guodong, Professor GAO Feng and Professor YUEN Ming Fai as independent non-executive Directors.